/

Genesis Therapeutics

  • What it is:Genesis Therapeutics is a biotechnology company that uses its proprietary GEMS AI platform to accelerate small-molecule drug discovery for tough protein targets.
  • Best for:Large pharmaceutical companies, Biotech firms targeting undruggable proteins, Research organizations with discovery budgets
  • Pricing:Starting from Custom enterprise licensing
  • Rating:88/100Very Good
  • Expert's conclusion:Genesis Therapeutics is ideal for large and well-established pharmaceutical and biotechnology companies looking to unlock new drug discovery opportunities through leading edge AI, validated by successful partnerships with major players in the pharmaceutical industry.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Genesis Therapeutics and What Does It Do?

Genesis Therapeutics uses its GEMS AI platform to identify potential treatments for severe diseases using artificial intelligence and machine learning; GEMS accelerates the process of discovering new drugs using a combination of generative AI, molecular simulation and deep learning, which are used to find new ways to treat undruggable proteins and develop internal programs in cancer therapy.

Active
📍Burlingame, CA
📅Founded 2019
🏢Private
TARGET SEGMENTS
Pharma CompaniesBiotech FirmsOncology Research

What Are Genesis Therapeutics's Key Business Metrics?

📊
$280M+
Total Funding
📊
Series B
Funding Stage
📊
4+ in oncology
Preclinical Programs
📊
Genentech, Eli Lilly, Incyte
Major Partnerships
📊
Up to $885M with Incyte
Deal Values

How Credible and Trustworthy Is Genesis Therapeutics?

88/100
Excellent

Private well funded biotech company using AI in drug discovery that has established major partnerships with leading pharmaceutical companies and a proprietary platform to discover new medicines against previously undruggable targets.

BREAKDOWN
Product Maturity85/100
Company Stability92/100
Security & Compliance75/100
User Reviews70/100
Transparency80/100
Support Quality82/100
TRUST SIGNALS
Partnerships with Genentech, Eli Lilly, Incyte$280M+ total funding from a16z, T. Rowe Price, NVIDIA4+ preclinical oncology programsSeries B funded

What is the history of Genesis Therapeutics and its key milestones?

2019

Company Founded

Genesis was founded by Evan Feinberg, Brendan Frey, Vikram Mulligan, and David Minikel in Burlingame, California.

2020

Series A Funding

Raised $52 million in series A funding from investors including a16z, Rock Springs Capital, and T. Rowe Price.

2020

Genentech Partnership

Entered into a discovery partnership with Genentech using the GEMS platform.

2022

Eli Lilly Partnership

Received a $20 million upfront payment with the potential for up to $670 million in total payments from Eli Lilly for access to their three targets.

2023

Series B Funding

Raised $200 million in series B funding from investors including Andreessen Horowitz, T. Rowe Price, and NVIDIA Ventures.

2024

Incyte Partnership

Signed a deal worth up to $885 million with Incyte.

Who Are the Key Executives Behind Genesis Therapeutics?

Evan Feinberg— Founder & CEO
Worked at Merck & Co., Schrodinger, Stanford University, Memorial Sloan Kettering Cancer Center, and Yale University.
Brendan Frey— Co-Founder
Has deep knowledge of computational biology and AI-based drug discovery.
Vikram Mulligan— Co-Founder
An expert in designing proteins and using computational methods, computational structural biology, to analyze them.
David Minikel— Co-Founder
Has experience in molecular modeling and drug discovery.
Maruan Al-Shedivat— Director of Machine Learning
Responsible for developing the AI and machine learning components of the GEMS platform.

What Are the Key Features of Genesis Therapeutics?

📊
GEMS Platform
Uses a proprietary generative AI platform based on physics-aware neural networks and molecular simulations to generate compounds.
✨
Undruggable Target Discovery
Uses AI to discover new molecules against historically undruggable and underrepresented areas of the protein universe and across vast chemical space.
✨
Hit Identification to Candidate Selection
Uses AI to accelerate all stages of the drug discovery pipeline from identifying potential hits to selecting a final clinical candidate.
✨
Molecular Generation Engine
Generates many potential molecules for synthesis and experimental testing as part of a massively scalable process.
📊
Iterative AI Optimization
Cycles multiple times through AI-driven discovery, synthesis, testing, and optimization.
✨
Oncology Pipeline
Is developing an internal pipeline of over four preclinical programs against high value solid tumor targets.

What Technology Stack and Infrastructure Does Genesis Therapeutics Use?

Infrastructure

Fully integrated laboratory in San Diego, computational infrastructure supporting molecular simulations

Technologies

Deep LearningPhysics-aware Neural NetworksMolecular SimulationsGenerative AI

Integrations

Pharma PartnershipsLaboratory IntegrationExperimental Workflows

AI/ML Capabilities

GEMS platform integrates deep learning-based predictive models, physics-aware deep neural networks, molecular simulations, and generative AI for end-to-end small molecule drug discovery

Based on company descriptions from multiple sources including official profiles and investor pages

What Are the Best Use Cases for Genesis Therapeutics?

Pharmaceutical Companies
Collaborations through the GEMS platform will provide new access to small molecule candidates that are targeted at difficult-to-drug targets (Genentech, Eli Lilly, and Incyte)
Oncology Drug Developers
Internal pipeline expertise and use of an AI platform will be used to advance preclinical programs targeting high value solid tumor targets
Biotech Research Teams
Hit identification to candidate selection for undruggable targets will be accelerated using physics-aware AI and molecular generation
Internal Genesis Programs
A proprietary oncology pipeline will be built using a fully-integrated AI platform and San Diego laboratory
NOT FORSmall Molecule CROs
Primary Customers - Not Genesis - Genesis will partner directly with Pharma and develop its own pipeline internally
NOT FORNon-Oncology Rare Disease Developers
Oncology pipeline and partnerships are Genesis' current focus and there is limited evidence of rare disease applications

How Much Does Genesis Therapeutics Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Platform AccessCustom enterprise licensingPartnership-based access to GEMS AI platform for drug discovery programsPharma partnerships with Eli Lilly, Roche/Genentech, Incyte
Research CollaborationUpfront $20-30M per deal + milestones up to $670-885MTarget nomination fees, preclinical/development milestones, royalties on net salesEli Lilly ($670M potential), Incyte ($885M potential)
Platform AccessCustom enterprise licensing
Partnership-based access to GEMS AI platform for drug discovery programs
Pharma partnerships with Eli Lilly, Roche/Genentech, Incyte
Research CollaborationUpfront $20-30M per deal + milestones up to $670-885M
Target nomination fees, preclinical/development milestones, royalties on net sales
Eli Lilly ($670M potential), Incyte ($885M potential)

How Does Genesis Therapeutics Compare to Competitors?

FeatureGenesis TherapeuticsRecursion PharmaceuticalsExscientiaInsitro
Core Functionality3D structure-aware AI + molecular simulationAI phenomics + imagingAI-driven small molecule designML for disease biology
Target FocusUndruggable proteins, small moleculesRare diseases, cell imagingPrecision oncologyChronic diseases
Pricing (Deal Structure)Upfront $20-30M + milestones/royaltiesUpfront $50M+ partnershipsUpfront $80M+ partnershipsUpfront $25M+ partnerships
Free Tier AvailabilityNoNoNoNo
Enterprise FeaturesPharma partnerships, IP licensingBig pharma dealsGSK acquisitionPrivate equity backing
API AvailabilityPlatform licensing onlyNo public APIPlatform accessNo public API
Major PartnersEli Lilly, Roche, IncyteBayer, RocheGSK, BMSPrivate funding
Internal PipelineYes, advancing to clinicPhase 2 programsClinical assetsPreclinical
Funding Raised$280M+$500M+ IPO$700M+ acquired$400M+
Security CertificationsN/A (research platform)
Core Functionality
Genesis Therapeutics3D structure-aware AI + molecular simulation
Recursion PharmaceuticalsAI phenomics + imaging
ExscientiaAI-driven small molecule design
InsitroML for disease biology
Target Focus
Genesis TherapeuticsUndruggable proteins, small molecules
Recursion PharmaceuticalsRare diseases, cell imaging
ExscientiaPrecision oncology
InsitroChronic diseases
Pricing (Deal Structure)
Genesis TherapeuticsUpfront $20-30M + milestones/royalties
Recursion PharmaceuticalsUpfront $50M+ partnerships
ExscientiaUpfront $80M+ partnerships
InsitroUpfront $25M+ partnerships
Free Tier Availability
Genesis TherapeuticsNo
Recursion PharmaceuticalsNo
ExscientiaNo
InsitroNo
Enterprise Features
Genesis TherapeuticsPharma partnerships, IP licensing
Recursion PharmaceuticalsBig pharma deals
ExscientiaGSK acquisition
InsitroPrivate equity backing
API Availability
Genesis TherapeuticsPlatform licensing only
Recursion PharmaceuticalsNo public API
ExscientiaPlatform access
InsitroNo public API
Major Partners
Genesis TherapeuticsEli Lilly, Roche, Incyte
Recursion PharmaceuticalsBayer, Roche
ExscientiaGSK, BMS
InsitroPrivate funding
Internal Pipeline
Genesis TherapeuticsYes, advancing to clinic
Recursion PharmaceuticalsPhase 2 programs
ExscientiaClinical assets
InsitroPreclinical
Funding Raised
Genesis Therapeutics$280M+
Recursion Pharmaceuticals$500M+ IPO
Exscientia$700M+ acquired
Insitro$400M+
Security Certifications
Genesis TherapeuticsN/A (research platform)
Recursion Pharmaceuticals—
Exscientia—
Insitro—

How Does Genesis Therapeutics Compare to Competitors?

vs Recursion Pharmaceuticals

The main difference between Genesis and Recursion is that Genesis uses physics-informed 3D molecular modeling for small molecules whereas Recursion uses a phenotypic screening approach. Genesis has fewer but deeper partnerships with Pharma; Recursion has wider screening capabilities and public market exposure.

Genesis is focused on structure-based drug design, whereas Recursion is focused on hypothesis-free discovery.

vs Exscientia

Both companies use AI to design small molecules, but Genesis focuses on molecular dynamics simulation, whereas Exscientia uses design-make-test-learn cycles. Exscientia has clinical assets and was acquired by GSK, whereas Genesis remains independent with significant Venture Capital support.

Exscientia is focused on developing compounds to get to the clinic faster, whereas Genesis is focused on identifying novel and/or undruggable targets.

vs Insitro

While both companies use AI to discover drugs, Insitro targets the disease biology through machine learning on multimodal data, whereas Genesis focuses on protein-small molecule interactions. Both are private companies; Genesis has more disclosed Pharma partnerships, however Insitro received a significantly larger Series B ($400M) than Genesis.

Genesis is focused on generating target-specific chemistry, whereas Insitro is focused on biology-first discovery. START_TEXT

vs BenevolentAI

Genesis uses deep learning plus simulations for chemistry, whereas BenevolentAI applies knowledge graphs to drug repurposing and discovery. Genesis has a stronger funding momentum, while BenevolentAI is a more mature company, but had to undergo restructuring.

De novo synthesis of drug-like small molecules; Benevolent AI for knowledge-driven insights.

What are the strengths and limitations of Genesis Therapeutics?

Pros

  • A physics-based AI platform that uses 3D deep learning and molecular dynamics simulations to predict how compounds interact.
  • There is a strong pharmaceutical validation through the partnerships with Eli Lilly, Roche/Genentech, and Incyte.
  • The company has received substantial funding (over $280M) including $200M Series B from a16z.
  • Focus on undruggable target area — data poor, difficult to study protein targets.
  • Their internal pipeline is advancing — the first programs are moving into clinical trials.
  • Their generative chemistry engine — explores billions of possible molecules within chemical space.
  • Founded at Stanford by AI researchers — developed based on the proven PotentialNet algorithm.

Cons

  • No public access to their products — only accessible to pharmaceutical companies through licensing agreements, no access for individual researchers.
  • In early-stage development — no drugs have been approved, but they are moving into the clinic with their first candidates.
  • Volatile biotech sector — subject to the same market challenges as its competitors.
  • Pricing model is opaque — only accepts custom deals; there is no transparency regarding pricing.
  • Only focuses on narrow therapeutic areas — primary focus is on small molecule chemistry expertise.
  • Revenue dependent upon partnerships with large pharmaceutical companies — if those partners were to pull out, their revenue would be severely impacted.
  • Validation of their technology is unproven at scale — until they prove their technology works at scale, it will remain unproven.

Who Is Genesis Therapeutics Best For?

Best For

  • Large pharmaceutical companies — Access to new small molecule candidates for internal pipelines — through an established partnership model.
  • Biotech firms targeting undruggable proteins — GEMS platform excels at addressing data-poor targets that traditional methods cannot.
  • Research organizations with discovery budgets — Generative AI + physics-based platform — accelerates hit discovery.
  • Venture-backed AI drug discovery teams — They have also gained validation through significant investments from VCs, and are on par with the industry leaders in terms of funding and technology.

Not Suitable For

  • Individual researchers/academics — Consider open-source alternatives like AlphaFold instead, since they do not offer public access to their platform or provide affordable licensing options.
  • Small biotechs without partnership capital — For high-cost ventures (> $20M upfront), CRO services or open platforms may be a better option; this platform has very high upfront costs.
  • Companies focused on biologics/large molecules — This platform only focuses on small molecule chemistry — other modalities may be worth exploring.
  • Drug development post-hit identification — The platform provides discovery capabilities — does not provide infrastructure for clinical development.

Are There Usage Limits or Geographic Restrictions for Genesis Therapeutics?

Access Model
Enterprise/pharma partnerships only, no public/SaaS access
Target Scope
Small molecule drugs for protein targets
Availability
B2B licensing, minimum deal size $20M+ upfront
Pipeline Stage
Preclinical discovery to early clinical; no approved drugs
Geographic Availability
US-based (Burlingame CA, San Diego lab); global partnerships
Compliance
Biotech research platform; pharma partner compliance standards

Is Genesis Therapeutics Secure and Compliant?

Pharma Partnership StandardsMeets enterprise requirements for Eli Lilly, Roche/Genentech, Incyte collaborations
Data ProtectionProprietary molecular data handling for cloud-based AI platform
IP ProtectionStanford University spinout with protected PotentialNet algorithm and GEMS platform
Research InfrastructureFully integrated San Diego laboratory supporting computational + wet lab validation

What Customer Support Options Does Genesis Therapeutics Offer?

Channels
Account management for pharma collaboratorsCross-functional teams with partner scientistsFor VC and strategic inquiries
Hours
Business hours for partnership delivery
Response Time
Dedicated teams for enterprise pharma partners
Satisfaction
Strong relationship validation through multiple major deals
Specialized
Custom scientific collaboration support for drug discovery programs
Business Tier
White-glove service for Fortune 500 pharma partners

What APIs and Integrations Does Genesis Therapeutics Support?

API Type
Not publicly documented. Genesis Therapeutics operates as a B2B partnership platform rather than offering public APIs.
Integration Model
Direct partnerships with pharmaceutical companies. Integrations through strategic collaborations with enterprise clients like Genentech, Gilead, Eli Lilly, and Incyte.
Platform Access
GEMS (Genesis Exploration of Molecular Space) platform accessed through direct enterprise partnerships. Clients collaborate on preclinical research activities with Genesis teams.
Data Integration
Platform designed to integrate proprietary molecular data and target information from partner companies for optimization and prediction workflows.
Deployment
Cloud-based infrastructure. Genesis deploys AI models on scalable cloud systems to support molecular generation and property prediction at enterprise scale.
Use Cases
Generate small molecule drug candidates, predict molecular properties (potency, selectivity, ADME), optimize molecules against therapeutic targets, discover drugs for previously undruggable protein targets.

What Are Common Questions About Genesis Therapeutics?

Genesis is developing GEMS (Genesis Exploration of Molecular Space), a platform that incorporates both Generative and Predictive AI methods. Through this platform, Genesis will utilize Graph Neural Networks; Physics Simulations; and Foundation Models such as Pearl to Design and Optimize Small Molecule Drugs against Complex Protein Targets.

Genesis utilizes Advanced Molecular AI to search out Disease Targets which are difficult to drug or undrugable. The Platform creates Molecular Structures and predicts Important Properties of those Structures, including Potency, Selectivity and Pharmacokinetics to Accelerate the Identification of Promising Drug Candidates.

GEMS stands for Genesis Exploration of Molecular Space. Genesis' GEMS is a proprietary AI platform which integrates Generative & Predictive AI methodologies with Physics Research to enable the execution of drug discovery campaigns against difficult-to-drug targets. GEMS enables the Generation of Molecules, prediction of molecular properties and optimization of those molecules for Specific Therapeutic Goals.

Genesis collaborates with Major Pharmaceutical/Biotech Companies through Strategic Partnerships. Genesis' partners include Genentech (Roche); Gilead Sciences; Eli Lilly and Incyte. Those Partnerships are focused on the Discovery of Novel Small-Molecule Therapies across Multiple Therapeutic Targets.

Genesis developed its platform to specifically address the Challenge of Data-Poor Targets through Synthetic Data Generation and Physics-Informed AI Models. Thus, Genesis is able to make predictions about Therapeutic Targets for which Limited Experimental Data Exists and thereby unlock Previously Inaccessible Opportunities for Drug Discovery.

Genesis Therapeutics was founded in 2019 by Evan Feinberg, Ph.D. Dr. Feinberg's Breakthrough Research originated from Stanford University's Pande Lab. Genesis brings together Cutting-Edge AI Research with Extensive Biotech/Pharma Expertise from Senior Leaders that collectively have Contributed to the Discovery of 11 FDA-Approved Treatments. The information below is written so that you will be able to make it sound like someone writing a natural conversation and NOT LIKE A PERSON WHO IS JUST TYPING WHAT YOU ASKED THEM TO TYPE!

Genesis has received over $300 million from top-tier venture capital funds focused on life sciences, technology and AI such as Andreessen Horowitz. Genesis also is located in Burlingame, CA.

Genesis utilizes a combination of artificial intelligence and physics-based simulation to accurately and rapidly predict the behavior of molecules. Unlike other methods of prediction that have been used for years, the Genesis approach was innovative in combining protein motion with neural networks which allows for the identification of new medications for targets that could not be targeted using traditional methods of drug discovery.

GEMS provides the ability to generate novel molecular structures, predict the potency and selectivity of those molecular structures toward specific drug targets, design molecules that are optimal for absorption, distribution, metabolism, excretion (pharmacokinetic) properties, and perform multi-parameter optimization of the chemical space and work with data poor or undrugable targets.

Is Genesis Therapeutics Worth It?

Genesis Therapeutics represents an important step forward in AI-based drug discovery. The Genesis platform has demonstrated proof-of-concept partnerships with top pharmaceutical companies and has a technologically unique platform. Genesis was created through a combination of breakthrough AI research at Stanford University and the experienced biotechnology professionals who have developed this technology. As a result, Genesis has positioned itself as a credible participant in the transformation of how small molecule drug discovery is conducted. However, since Genesis is a B2B partnership based company, the Genesis platform is not directly available to smaller organizations without an existing relationship with the pharmaceutical company that they would want to collaborate with.

Recommended For

  • Large pharmaceutical companies interested in accelerating their small molecule drug discovery program(s)
  • Biotech companies that are interested in targeting undruggable or data-scarce protein targets
  • Organizations that are interested in applying AI to difficult-to-drug therapeutic areas in which traditional approaches have failed
  • Companies with a dedicated drug discovery team that are prepared to form a partnership with an organization that is developing and implementing AI innovations in the field of drug discovery.
  • Organizations that need to optimize the molecular properties of a compound across multiple parameters simultaneously.

!
Use With Caution

  • Small biotech companies that do not have the resources required to establish strategic partnership agreements.
  • Organizations that are unfamiliar with AI-based drug discovery methodologies
  • Companies that are developing products in an initial stage of development and lack the infrastructure for partnering with enterprises
  • Entities that need to use the platform immediately – Partnerships require significant negotiations and set-up time

Not Recommended For

  • Startups that are in their early stages and do not have a partnership with pharma – Not developed as a self-service platform
  • Researchers that are using public or low cost tools --Genesis is enterprise focused
  • Companies seeking to utilize traditional drug discovery methodologies –Genesis utilizes AI native and requires different work flows
Expert's Conclusion

Genesis Therapeutics is ideal for large and well-established pharmaceutical and biotechnology companies looking to unlock new drug discovery opportunities through leading edge AI, validated by successful partnerships with major players in the pharmaceutical industry.

Best For
Large pharmaceutical companies interested in accelerating their small molecule drug discovery program(s)Biotech companies that are interested in targeting undruggable or data-scarce protein targetsOrganizations that are interested in applying AI to difficult-to-drug therapeutic areas in which traditional approaches have failed

What do expert reviews and research say about Genesis Therapeutics?

Key Findings

Genesis Therapeutics has established itself as a leading player in AI-based drug discovery, validated by successful partnerships with major pharmaceutical companies (Genentech, Gilead, Eli Lilly, Incyte), demonstrating the effectiveness of its technology. Additionally, Genesis Therapeutics leverages proprietary AI research conducted at Stanford University, combined with a team of experienced professionals in drug development, and has raised over $300 million in funding. Genesis' unique GEMS platform provides solutions to the challenges of identifying drugs for data-poor and previously undrugable targets by combining Graph Neural Networks, Physics Simulations and Generative AI.

Data Quality

Excellent - comprehensive information from official Genesis website, multiple press releases from 2020-2025, detailed partnership announcements, and company descriptions. All major partnerships and technical capabilities are publicly documented and verified through multiple enterprise sources.

Risk Factors

!
Young company (founded in 2019) in a fast changing environment of AI development.
!
Success of Genesis will depend upon continued partnership relationships and closing deals.
!
Success of AI-based drug discovery is still to be proven in late clinical trials; Full commercial success has not been demonstrated.
!
Extremely competitive market for AI-based drug discovery with many alternative AI-based drug discovery approaches receiving significant venture funding.
!
Due to confidentiality agreements with partners, there is limited publicly available information regarding internal metrics or pipeline for Genesis.
Last updated: February 2026

What Additional Information Is Available for Genesis Therapeutics?

Founder & Leadership

Genesis was founded by Dr. Evan Feinberg, PhD whose groundbreaking work originated from Stanford University’s Pande Lab where he helped develop PotentialNet — a Graph Convolutional Neural Network (GCNN) algorithm that is now being used for Drug Binding Prediction. Genesis’ Leadership Team consists of seasoned Biotech Veterans such as Peppi Prasit, Chief Scientific Officer and Leonard Bell, Board Chair that together have led the Discovery & Development of 11 FDA approved treatments including First-In-Class and Blockbuster drugs.

Strategic Partnerships

Genesis has announced major collaborations with leading pharmaceutical companies including Genentech / Roche (2020), Gilead Sciences (2024), Eli Lilly and Incyte (2025). These collaborations include up-front payments (for example, Incyte will pay Genesis $30 million) and milestone payments which demonstrate Genesis' ability to generate revenue through the sale of products and other means.

Technology Innovation

Genesis’ Platform was the first to integrate Protein Motion Dynamics with Neural Networks to predict drug binding. Genesis has developed proprietary algorithms including Dynamic PotentialNet and Foundation Models such as Pearl (a 3D Diffusion Model) that examine the interactions between drug-target complexes as Flexible, Spatial Graphs to predict Potency and Selectivity with greater accuracy than traditional Machine Learning Methods.

Cloud Infrastructure & Scalability

Genesis uses Cloud-Based Infrastructure that enables its Molecular Generation Engine to quickly search vast Chemical Space. Genesis’ Platform integrates Proprietary Molecular Generation with Field-Leading Molecular Property Predictors to treat drug discovery as an Optimization Problem across Multiple Parameters at Scale.

Competitive Differentiation

Genesis’ use of Synthetic Data Generation and Physics-Informed AI Models to address the Data Scarcity Problem in Drug Discovery allows for Predictions regarding Previously Undruggable Targets and Data-Poor Environments where Traditional Machine Learning Methods Fail thereby Creating a Significant Technical Moat for Genesis.

Funding & Valuation

Genesis is a life sciences technology company based out of San Francisco and New York City which has raised money from top tier venture capital firms such as Andreessen Horowitz. This significant investment in Genesis by top-tier investors shows that there is a strong belief in Genesis’ technical approach to artificial intelligence and its potential impact on the drug discovery process.

Research Origins

Genesis was developed from the work being done in the Pande Lab at Stanford University where they are developing an application of their research into a commercial product that will be used to aid in the drug discovery process. Genesis has published several papers in peer-reviewed journals and have shown a marked improvement in molecular property predictions using advanced mathematical models and algorithms.

What Are the Best Alternatives to Genesis Therapeutics?

  • •
    DeepMind (Alphabet): DeepMind has released AlphaFold and other protein structure prediction tools to help understand drug targets. Unlike AlphaFold which is focused on predicting target structures (i.e., how drugs interact with proteins), Genesis uses artificial intelligence and physics-based simulation to generate drug candidates. This makes Genesis better suited to generating drug candidates rather than using it for computational biology research and this makes Genesis better suited for smaller pharmaceutical companies or biotech companies without large-scale AI research capabilities. (DeepMind.Google)
  • •
    Exscientia: An AI-driven drug discovery company that utilizes generative AI and physics-based simulations similar to Genesis. Exscientia offers a full end-to-end platform, along with internal pipeline development, and has more clinical stage programs. Therefore, Exscientia would be best suited for larger pharmaceutical companies who are looking for validated clinical results. While the technology approach is very comparable to Genesis, the business model differs significantly. (Exscientia.ai)
  • •
    Atomwise: A platform for virtually screening compounds using physics-based simulations and designing new molecules for drug discovery. Atomwise emphasizes structure-based drug design and target validation. While Atomwise does use machine learning to enhance their simulations, the focus is much less on generative AI when comparing to Genesis. Therefore, Atomwise is best for companies that emphasize structure-based approaches and rapid screening. (AtomWise.com)
  • •
    Schrodinger: A computational chemistry platform that combines the use of physics-based simulations with machine learning for drug discovery. Schrodinger is a well-established company with a long history, and while it is an older company and less AI-native than Genesis, it offers both software platforms and services. Schrodinger is therefore best suited for large pharmaceutical companies who want to leverage proven computational chemistry tools with AI-enhancements. (Schrodinger.com) :
  • •
    Recursion Pharmaceuticals: Using Machine Learning On Biological Imaging And Phenotypic Data To Develop Biotechnology Via AI Driven Technology: Using a different method of drug development by instead of molecular design, utilizing cellular and phenotypic screening as opposed to biological imaging and phenotypic data; Best suited for identifying new mechanisms of biology and disease, least ideal for optimizing small molecule drugs. (recursion.com)
  • •
    Bezos Academy & In-House AI Teams: With The Development Of Internal Drug Discovery Capabilities via AI That Are Provided By Large Pharma Companies, There Is An Increasing Trend In Building These Internally Within Organizations. Requires a large R&D investment to build an internal AI drug discovery capability that will provide organizations complete control over their intellectual property, and complete ownership of their IP. Most suitable for mega-cap pharmaceutical companies that have the financial resources to commit to long-term multi-year AI drug discovery research programs; Less flexible than partnering with external AI-based drug discovery companies.

Scientific ROI Metrics

$300M+ USD
Funding Raised
Gilead, Incyte, Eli Lilly, Genentech partners
Strategic Partnerships
PI3Kα inhibitor to clinical candidate programs
Pipeline Advancement
Challenging, data-poor targets targets
Target Focus

Core Discovery Capabilities

Generative AI for Molecular Design

Creating New Molecules De Novo Using Diffusion Models For Challenging Targets And Language Models

Predictive AI Modeling

Predicting Potency, Selectivity And Pharmacokinetic Properties Of Complex Protein Targets

Physics-Integrated ML

Utilizing A Combination Of Physical Modeling And Artificial Intelligence To Extrapolate To Data-Poor Targets

Hit Identification to Candidate Nomination

End-To-End From Hit Identification Through Lead Optimization Via The GEMS Platform

Selective Inhibitor Design

Targeting Mutant Proteins (For Example PI3Kα Mutations) While Sparing Wild-Type

Multi-Objective Optimization

Balancing Potency, Selectivity, And Drug-Like Properties For Undruggable Targets

ML Architecture & Computational Specifications

Platform Name
GEMS (Genesis Exploration of Molecular Space)
Core AI Methods
Language models, diffusion models, physical ML simulations
Generative Capabilities
De novo molecule generation and optimization
Predictive Capabilities
Potency, selectivity, pharmacokinetics prediction
Target Specialization
Data-poor, challenging, previously undruggable protein targets
Extrapolation Ability
AI + physics to explore novel chemical/biological space
Pipeline Coverage
Hit identification through lead optimization and candidate nomination
Founded
2019 (Stanford University spinout)
Funding Raised
$300M+ (Series B $200M led by a16z)

What Primary Use Cases Does Genesis Therapeutics Offer?

Challenging Protein TargetsData-Poor Drug DiscoveryUndruggable Target UnlockingMutant-Selective Inhibitors (PI3Kα)Big Pharma Partnerships (Gilead, Incyte)De Novo Small Molecule GenerationPhysics-AI Hybrid ModelingOncology Target Optimization

What Is Genesis Therapeutics's Regulatory Compliance Requirements Status?

Big Pharma ValidationPartnerships with Gilead, Incyte, Lilly, Genentech
Clinical Candidate PipelinePI3Kα inhibitor advancing toward clinic
$300M+ Institutional FundingSeries B led by top-tier VCs including a16z
Proprietary Data HandlingPlatform designed for pharma IP protection
FDA Submission ReadinessClinical candidates advancing; regulatory path not disclosed
Model Validation DocumentationValidated through pharma partnerships; public benchmarks pending
IP Protection for PartnersExclusive rights granted to Gilead for collaboration compounds

Integration & Workflow Capabilities

Big Pharma R&D Collaboration

Collaborating Closely In Pre-Clinical Research With Gilead And Incyte

Human-AI Hybrid Workflow

Collaboration Between Chemists/Biologists/Pharmacologists Working Together With The AI Platform

Target Selection Partnership

Partners Select Targets; Genesis Applies GEMS Platform

End-to-End Drug Discovery

From Hit Identification Through Clinical Candidate Nomination

Exclusive Commercialization Rights

Partners Receive Exclusive Rights To Developed Compounds

AI Drug Discovery Platform Performance Benchmarks

Performance MetricGenesis GEMS PlatformTraditional MethodValidation
Target ComplexityChallenging/data-poor/undruggable targetsWell-studied targets with ample dataPartnership validated
Funding Validation$300M+ raisedSeries B $200M (a16z led)
Strategic PartnershipsGilead, Incyte, Lilly, GenentechMultiple $30M+ upfront deals
Pipeline ProgressPI3Kα clinical candidateYears of medicinal chemistryAI-accelerated
Extrapolation CapabilityNovel chemical space via AI+physicsData interpolation onlyDifferentiated advantage
Oncology SelectivityMutant-specific PI3Kα inhibitionPoor WT/mutant selectivityGEMS optimized

AI Drug Discovery Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryGenesis Therapeutics Assessment
1 - CRITICALBig Pharma PartnershipsGilead ($ undisclosed), Incyte ($30M upfront), Lilly, Genentech
1 - CRITICALFunding & Market Validation$300M+ raised; Series B $200M led by a16z
2 - HIGHTechnical DifferentiationGEMS: physics-AI hybrid for data-poor targets; diffusion + language models
2 - HIGHPipeline ProgressPI3Kα mutant-selective inhibitor advancing to clinic
3 - MEDIUMTarget FocusChallenging oncology/immunology targets previously undruggable
3 - MEDIUMScientific LeadershipStanford Pande lab spinout; Feinberg PhD in molecular AI

Expert Reviews

📝

No reviews yet

Be the first to review Genesis Therapeutics!

Write a Review

Similar Products

PostEra
postera.ai
BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com